HPV治疗性疫苗的研究进展  

Research progress of HPV therapeutic vaccine

作　　者：徐晓琪 王志莲[1] Xu Xiaoqi;Wang Zhilian(Shanxi Medical University,Shanxi Taiyuan 030001,China)

机构地区：[1]山西医科大学,山西太原030001

出　　处：《现代肿瘤医学》2020年第18期3275-3278,共4页Journal of Modern Oncology

摘　　要：宫颈癌是影响全球女性健康的公共卫生问题。持续的高危型HPV感染是宫颈癌的主要致病因素。目前,HPV预防性疫苗已经在全球范围内逐渐广泛开展,但其对已感染HPV的女性没有治疗作用。迄今,多种治疗性疫苗已用于临床前模型和临床试验,包括肽和蛋白质疫苗、活载体疫苗、DNA疫苗等,并已经显示出良好的安全性和耐受性,为宫颈癌的防治工作带来了希望和动力。但其仍存在免疫原性低、需要寻找更多新的靶抗原基因等不足,仍需进一步研究。Cervical cancer is a public health problem affecting the health of women all over the world.Persistent high risk HPV infection is a major risk factor for cervical cancer.At present,HPV prophylactic vaccine has been widely used all over the world,but it has no therapeutic effect on women who have been infected with HPV.To date,a variety of therapeutic vaccines have been used in preclinical models and clinical trials,including peptide and protein vaccines,live vector vaccines,DNA vaccines,and have shown good safety and tolerance,for the prevention and treatment of cervical cancer to bring hope and power.However,there are still many shortcomings,which still need to be further studied.

关 键 词：人乳头瘤状病毒 宫颈癌 治疗性疫苗 

分 类 号：R733.7[医药卫生—肿瘤]